Transcriptional regulation of connexin 43 expression by retinoids and carotenoids: Similarities and differences

Molecular Carcinogenesis

Volumn 43, Issue 2, 2005, Pages 75-85

  Vine, Alex L ^a,b   Leung, Yee M ^a   Bertram, John S ^a  

^a UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Carotenoids; Connexin43; Reporter gene; Retinoid receptors; Retinoids; Tumor suppressor gene

Indexed keywords

ASTAXANTHIN; BETA CAROTENE; CAROTENOID; CONNEXIN 43; GAP JUNCTION PROTEIN; LUCIFERASE; LYCOPENE; MESSENGER RNA; RECEPTOR BLOCKING AGENT; RETINOIC ACID RECEPTOR; RETINOID; RO 415253; TRANSCRIPTION FACTOR SP1; TRANSCRIPTION FACTOR SP3; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL COMMUNICATION; CONTROLLED STUDY; DNA RESPONSIVE ELEMENT; GAP JUNCTION; GEL MOBILITY SHIFT ASSAY; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENE INDUCTION; HALF LIFE TIME; MOUSE; NONHUMAN; PRECANCER; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN SYNTHESIS; REPORTER GENE; RETINOIC ACID RESPONSIVE ELEMENT; SITE DIRECTED MUTAGENESIS; TRANSCRIPTION INITIATION; TRANSCRIPTION INITIATION SITE; TRANSCRIPTION REGULATION;

ANIMALS; BASE SEQUENCE; CAROTENOIDS; CONNEXIN 43; CONSENSUS SEQUENCE; GENE EXPRESSION REGULATION; GENES, REPORTER; HUMANS; MICE; MICE, INBRED C3H; MICE, KNOCKOUT; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; RATS; RECEPTORS, RETINOIC ACID; RETINOIDS; RNA, MESSENGER; TRANSCRIPTION, GENETIC; TRANSFECTION;

EID: 20344405706     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/mc.20080     Document Type: Article

References (56)

1. Simon AM, Goodenough DA. Diverse functions of vertebrate gap junctions. Trends Cell Biol 1998;8:477-483.
2. Sohl G, Willecke K. An update on connexin genes and their nomenclature in mouse and man. Cell Commun Adhes 2003;10:173-180.
3. Teunissen BE, Jansen AT, van Amersfoorth SC, O'Brien TX, Jongsma HJ, Bierhuizen MF. Analysis of the rat connexin 43 proximal promoter in neonatal cardiomyocytes. Gene 2003;322:123-136.
4. Lefebvre DL, Piersanti M, Bai XH, Chen ZQ, Lye SJ. Myometrial transcriptional regulation of the gap junction gene, Connexin-43. Reprod Fertil Dev 1995;7:603-611.
5. Loewenstein WR. Junctional intercellular communication and the control of growth. Biochim Biophys Acta 1979;560:1-65.
6. Yu W, Dahl G, Werner R. The connexin43 gene is responsive to oestrogen. Proc R Soc Lond B: Biol Sci 1994;255:125-132.
7. Cowan DB, Lye SJ, Langille BL. Regulation of vascular connexin43 gene expression by mechanical loads. Circulation Res 1998;82:786-793.
8. Clairmont A, Sies H. Evidence for a posttranscriptional effect of retinoic acid on connexin43 gene expression via the 3′-untranslated region. FEBS Lett 1997;419:268-270.
9. Schiavi A, Hudder A, Werner R. Connexin43 mRNA contains a functional internal ribosome entry site. FEBS Lett 1999;464:118-122.
10. Neveu M, Bertram JS. Gap junctions and neoplasia. Adv Mol Cell Biol 30, 221-262. 2000. Advances in Cellular and Molecular biology Greenwich, CT: JAI Press.
11. Chen Y, Huhn D, Knosel T, Pacyna-Gengelbach M, Deutschmann N, Petersen I. Downregulation of connexin 26 in human lung cancer is related to promoter methylation. Int J Cancer 2005;113:14-21.
12. Chen JT, Cheng YW, Chou MC, et al. The correlation between aberrant connexin 43 mRNA expression induced by promoter methylation and nodal micrometastasis in non-small cell lung cancer. Clin Cancer Res 2003;9:4200-4204.
13. Vine AL, Bertram JS. Cancer chemoprevention by connexins. Cancer Metastasis Rev 2002;21:199-216.
14. King TJ, Lampe PD. Mice deficient for the gap junction protein Connexin32 exhibit increased radiation-induced tumorigenesis associated with elevated mitogen-activated protein kinase (p44/Erk1, p42/Erk2) activation. Carcinogenesis 2004;25:669-680.
15. Avanzo JL, Mesnil M, Hernandez-Blazquez FJ, et al. Increased susceptibility to urethane-induced lung tumors in mice with decreased expression of connexin43. Cardnogenesis 2004;25:1973-1982.
16. Quo H, Acevedo P, Parsa DF, Bertram JS. The gap-junctional protein connexin 43 is expressed in dermis and epidermis of human skin: Differential modulation by retinoids. J Invest Dermatol 1992;99:460-467.
17. Rogers M, Berestecky JM, Hossain MZ, et al. Retinoid-enhanced gap junctional communication is achieved by increased levels of connexin 43 mRNA and protein. Mol Cardnog 1990;3:335-343.
18. Lippman SC, Lotan R. Advances in the development of retinoids as chemopreventive agents. J Nutr 2000;130:479S-482S.
19. Zhang L-X, Cooney RV, Bertram JS. Carotenoids up-regulate connexin43 gene expression independent of their pro-vitamin A or antioxidant properties. Cancer Res 1992;52:5707-5712.
20. Mayne ST, Lippman S. Cancer prevention: Chemopreventive agents. Retinoids and carotenoids. In: DeVita VT, Hellman S, Rosenberg SA, editors. Principles and practice of oncology. Philadelphia, PA: Lippencott-Raven; 1997. pp 585-599.
21. Zhang L-X, Cooney RV, Bertram JS. Carotenoids enhance gap junctional communication and inhibit lipid peroxidation in C3H/10T1/2 cells: Relationship to their cancer chemopreventive action. Carcinogenesis 1991;12:2109-2114.
22. Mehta PP, Bertram JS, Loewenstein WR. The actions of retinoids on cellular growth correlate with their actions on gap junctional communication. J Cell Biol 1989;108:1053-1065.
23. King TJ, Fukushima L, Bertram JS. Connexins and carcinogenesis: Upregulated expression of connexin43 by cancer preventive agents or by gene transfer decreases proliferation and expression of neoplasia. In: Werner R, editor. Gap Junctions. Amsterdam: IOS Press; 1998. pp 357-361.
24. Chambon P. A decade of molecular biology of retinoic acid receptors. FASEB J 1996;10:940-954.
25. McEwan IJ. Gene regulation through chromatin remodelling by members of the nuclear receptor superfamily. Biochem Soc Trans 2000;28:369-373.
26. Teicher VB, Kucharski N, Martin HD, van der SP, Sies H, Stahl W. Biological activities of Apo-canthaxanthinoic acids related to gap junctional communication. Arch Biochem Biophys 1999;365:150-155.
27. King TJ, Khachik F, Bortkiewicz H, Fukushima L, Morioka S, Bertram JS. Metabolites of dietary carotenoids as potential cancer preventive agents. Pure and Appl Chem 1997;69:2135-2140.
28. Kiefer C, Hessel S, Lampert JM, et al. Identification and characterization of a mammalian enzyme catalyzing the asymmetric oxidative cleavage of provitamin A. J Biol Chem 2001;276:14110-14116.
29. Lee SJ, Bai SK, Lee KS, Namkoong S, et al. Astaxanthin inhibits nitric oxide production and inflammatory gene expression by suppressing I(kappa)B kinase-dependent NF-kappaB activation. Mol Cell 2003;16:97-105.
30. Astorg P, Gradelet S, Leclerc J, Canivenc M-C, Siess M-H. Effects of beta-carotene and canthaxanthin on liver xenobiotic-metabolizing enzymes in the rat. Fd Chem Toxic 1996;32:735-742.
31. Meyskens FL, Jr., Surwit E, Moon TE, et al. Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-trans-retinoic acid: A randomized trial. J Natl Cancer Inst 1994;86:539-543.
32. Hong WK, Lippman SM, Itri LM, et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 1990;323:795-801.
33. Mayne ST, Cartmel B, Baum M, et al. Randomized trial of supplemental β-carotene to prevent second head and neck cancer. Cancer Res 2001;61:1457-1463.
34. Garewal HS, Katz RV, Meyskens F, et al. Beta-carotene produces sustained remissions in patients with oral leukoplakia: Results of a multicenter prospective trial. Arch Otolaryngol Head Neck Surg 1999;125:1305-1310.
35. King TJ, Fukushima LH, Hieber AD, Shimabukuro KA, Sakr WA, Bertram JS. Reduced levels of connexin43 in cervical dysplasia: Inducible expression in a cervical carcinoma cell line decreases neoplastic potential with implications for tumor progression. Carcinogenesis 2000;21:1097-1109.
36. Sakr W, Tabaska P, Kucuk O, Bertram JS. Differential expression of connexin 43 in normal, preneoplastic and neoplastic squamous epithelium of the upper aerodigestive tract. Proc AACR 1996;37:269.
37. Cooney RV, Kappock TJ, Pung A, Bertram JS. Solubilization, cellular uptake, and activity of β-carotene and other carotenoids as inhibitors of neoplastic transformation in cultured cells. Methods Enzymol 1993;214:55-68.
38. Carystinos GD, Kandouz M, Alaoui-Jamali MA, Batist G. Unexpected induction of the human connexin 43 promoter by the ras signaling pathway is mediated by a novel putative promoter sequence. Mol Pharmacol 2003;63:821-831.
39. Tuthill MC, Wada RK, Arimoto JM, et al. N-myc oncogene expression in neuroblastoma is driven by Sp1 and Sp3. Mol Genet Metab 2003;80:272-280.
40. Osborne SA, Tonissen KF. pRL-TK induction can cause misinterpretation of gene promoter activity. Biotechniques 2002;33:1240-1242.
41. Fort P, Rech J, Vie A, et al. Regulation of c-fos gene expression in hamster fibroblasts: Initiation and elongation of transcription and mRNA degradation. Nucleic Acids Res 1987;15:5657-5667.
42. Ai ZW, Fischer A, Spray DC, Brown AMC, Fishman GI. Wnt-1 regulation of connexin43 in cardiac myocytes. J Clin Investig 2000;105:161-171.
43. van der Heyden MA, Rook MB, Hermans MM, et al. Identification of connexin43 as a functional target for Wnt signalling. J Cell Sci 1998;111:1741-1749.
44. Echetebu CO, Ali M, Izban MG, MacKay L, Garfield RE. Localization of regulatory protein binding sites in the proximal region of human myometrial connexin 43 gene. Mol Hum Reprod 1999;5:757-766.
45. Fernandez-Cobo M, Stewart D, Drujan D, De Maio A. Promoter activity of the rat connexin 43 gene in NRK cells. J Cell Biochem 2001;81:514-522.
46. Shimada J, Suzuki Y, Kim SJ, Wang PC, Matsumura M, Kojima S. Transactivation via RAR/RXR-Sp1 interaction: Characterization of binding between Sp1 and GC box motif. Mol Endocrinol 2001;15:1677-1692.
47. Hossain MZ, Wilkens LR, Mehta PP, Loewenstein WR, Bertram JS. Enhancement of gap junctional communication by retinoids correlates with their ability to inhibit neoplastic transformation. Carcinogenesis 1989;10:1743-1748.
48. Hanusch M, Stahl W, Schulz WA, Sies H. Induction of gap junctional communication by 4-oxoretinoic acid generated from its precursor canthaxanthin. Arch Biochem Biophys 1995;317:423-428.
49. Acevedo P, Bertram JS. Liarozole potentiates the cancer chemopreventive activity of and the up-regulation of gap junctional communication and connexin43 expression by retinoic acid and β-carotene in 10T1/2 cells. Carcinogenesis 1995;16:2215-2222.
50. Stahl W, Hanusch M, Sies H. 4-oxo-retinoic acid is generated from its precursor canthaxanthin and enhances gap junctional communication in 10T1/2 cells. Adv Exp Med Biol 1996;387:121-128.
51. Clairmont A, Tessmann D, Sies H. Analysis of connexin43 gene expression induced by retinoic acid in F9 teratocarcinoma cells. FEBS Lett 1996;397:22-24.
52. Bertram JS. Structure activity relationships among various retinoids and their ability to inhibit neoplastic transformation and to increase cell adhesion in C3H/10T1/2 CL8 cell line. Cancer Res 1980;40:3141-3146.
53. Novak A, Dedhar S. Signaling through beta-catenin and Lef/Tcf. Cell Mol Life Sci 1999;56:523-537.
54. Chen ZQ, Lefebvre D, Bai XH, Reaume A, Rossant J, Lye SJ. Identification of two regulatory elements within the promoter region of the mouse connexin 43 gene. J Biol Chem 1995;270:3863-3868.
55. YU B, Datta PK, Bagchi S. Stability of the Sp3-DNA complex is promoter-specific: Sp3 efficiently competes with Sp1 for binding to promoters containing multiple Sp-sites. Nucleic Acids Res 2003;31:5368-5376.
56. Ammanamanchi S, Freeman JW, Brattain MG. Acetylated sp3 is a transcriptional activator. J Biol Chem 2003;278:35775-35780.